敬请投资者注意，受复活节假期影响，港股、欧洲股市和澳大利亚股市本周一休市。 特朗普列举8项非关税"作弊"手段，点名日本和欧盟，手段包括1.汇率操纵，2.增值税作为关税和出口补 贴，3.低于成本倾销，4.出口补贴和其他政府补贴，5.农业保护性标准（如欧盟禁止转基因玉米），6.防 护技术标准（如日本保龄球试验），7.假冒、盗版和知识产权盗窃（年损失超过1万亿美元），8.转运避 税。 中航信托宣布由建信信托、国投泰康信托来进行日常托管。虽然还没有正式官宣暴雷，但这个上百亿规 模的央企信托已经实质上雷了，之前多款面向社会投资者的信托产品已经停止兑付。中航信托之所以暴 雷，是因为之前重仓投资了房地产，恒大、融创、红星美凯龙的坑他们都踩了。另外有媒体报道，他们 在暴雷前曾经给内部员工进行提前兑付。目前，中航信托还有超过500亿的产品没有兑付。 A股方面，沪指上周累计涨1.19%、深成指跌0.54%、创业板指跌0.64%。市场持续缩量，周五创去 年"924"行情爆发以来新低。银行、房地产、综合、煤炭等板块逆市上涨，国防军工、农林牧渔、计算 机等板块跌幅居前。 港股方面，恒指上周累计涨2.3%，国指涨1.23%，恒生科技指数 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000661 证券简称：长春高新 公告编号：2025-045 长春高新技术产业（集团）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： □是 √否 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二）非经常性损益项目和金额 √适用 □不适用 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）声明：保证季度报告中财务信 息的真实、准确、完整。 3.第一季度报告是否经审计 ■ 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券 ...

长春高新的核心子公司金赛药业，作为公司生长激素业务的主要贡献者，2024年实现收入106.71亿元， 同比下降3.73%；归属于母公司所有者的净利润为26.78亿元，同比下降40.67%。2025年一季度，金赛药 业实现收入26.17亿元，同比增长5.94%，但归属于母公司所有者的净利润为5.35亿元，同比下降 38.31%。业绩下滑的主要原因是销售费用和研发投入的持续增加。公司为强化销售端竞争力，增加了 销售人员数量，同时加快了新产品的研发进程，导致相关费用大幅上升。 2024年，长春高新（000661）交出了一份令人瞩目的业绩报告，但其业绩表现却并不乐观。年报显示， 公司2024年实现营业收入134.66亿元，同比下降7.55%；归属于上市公司股东的净利润为25.83亿元，同 比下降43.01%。这是长春高新近20年来首次出现年度收入同比下滑的情况。更令人担忧的是，2025年 一季度，公司业绩颓势依旧，实现营业收入29.97亿元，同比下降5.66%；归属于上市公司股东的净利润 为4.73亿元，同比下降44.95%。 长春高新的业绩下滑与LPR的稳定形成了鲜明对比。公司业绩的疲软不仅反映了其主营业务面临的挑 ...

Core Viewpoint - Changchun High-tech's financial performance has significantly declined, with both revenue and net profit showing substantial decreases in 2024 and the first quarter of 2025 [4][6][10]. Financial Performance Summary - In 2024, Changchun High-tech reported revenue of 13.47 billion yuan, a decrease of 7.6% year-on-year, and a net profit attributable to shareholders of 2.58 billion yuan, down 43% from the previous year [6][7]. - The fourth quarter of 2024 saw a revenue drop to 3.08 billion yuan, a decline of 20.8% year-on-year, with a net profit loss of 206 million yuan, a decrease of 122.4% [7]. - For the first quarter of 2025, the company achieved revenue of 2.99 billion yuan, down 5.66% year-on-year, and a net profit of 472 million yuan, a decrease of 44.95% [9][10]. Subsidiary Performance - Jinsai Pharmaceutical, the core subsidiary of Changchun High-tech, reported a revenue of 10.67 billion yuan in 2024, a decrease of 3.73%, and a net profit of 2.68 billion yuan, down 40.67% [10]. - In the first quarter of 2025, Jinsai Pharmaceutical's revenue was 2.62 billion yuan, an increase of 5.94%, but its net profit decreased by 38.31% to 535 million yuan [10]. Shareholder Information - As of March 31, 2025, Changchun High-tech had a total of 125,097 shareholders, reflecting a decrease of 1.80% from the previous quarter [11].

Core Viewpoint - Changchun High-tech's 2024 annual report indicates a slight decline in revenue and profit due to increased R&D investment and external competitive pressures, with revenue at 13.466 billion and net profit at 2.583 billion [1] Financial Performance - In Q1 2025, the core subsidiary Jinsai Pharmaceutical reported a revenue of 2.617 billion, showing a return to growth year-on-year [1] - The company plans to distribute a cash dividend of 2.6 per 10 shares, totaling 1.047 billion, alongside a share buyback of 420 million, making the total return to shareholders 1.467 billion, which is 56.81% of the annual net profit [2] - Cumulatively, since its listing, the company has returned 4.967 billion to shareholders, exceeding its fundraising total by 159.25% [2] R&D Investment - R&D investment reached 2.690 billion in 2024, representing 19.97% of revenue, with an 11.20% year-on-year increase, positioning the company as a leader among 24 disclosed firms in the biopharmaceutical sector [4] - The company has a robust pipeline with 24 key products in clinical stages and plans to launch 10 new drugs covering 20 indications in the next five years [5][6] Product Development and Market Position - The company has received drug registration certificates for several products, including long-acting growth hormone for specific indications, and has 7 pipelines in the application stage and 9 in phase III clinical trials [5] - The company maintains a strong position in the growth hormone market, with 12 approved indications and significant revenue from Jinsai Pharmaceutical, which exceeded 10 billion [8][9] International Expansion - The company is accelerating international sales of growth hormone products, achieving a revenue of 99 million in foreign markets, a 454% increase year-on-year [9]

Core Viewpoint - Changchun High-tech has reported its first annual revenue decline in nearly 20 years, with a 7.55% decrease in revenue and a 43.01% drop in net profit for 2024 compared to the previous year [1][2]. Financial Performance - In 2024, the company achieved revenue of 13.466 billion yuan, down 7.55% year-on-year, and a net profit of 2.583 billion yuan, down 43.01% year-on-year [1]. - For Q1 2025, revenue was 2.997 billion yuan, a decrease of 5.66% year-on-year, with a net profit of 473 million yuan, down 44.95% year-on-year [1]. - The company’s main subsidiary, Jinsai Pharmaceutical, saw total revenue decrease by 3.73% to 10.671 billion yuan, despite a 454% increase in overseas sales [2]. - Baike Biological, another subsidiary, reported a revenue decline of 32.64% to 1.229 billion yuan and a net profit drop of 53.67% [2]. - Gaoxin Real Estate experienced a revenue decline of 17.32% to 756 million yuan and a net profit drop of 80.09% [3]. Business Segments - The company operates in four main segments: genetic engineering pharmaceuticals, biological vaccines, traditional Chinese medicine, and real estate, corresponding to its four subsidiaries [1]. - The only subsidiary showing positive growth was Huakang Pharmaceutical, but its revenue contribution is minimal, making it insufficient to offset the overall decline [3]. Investment and Strategy - To counteract the revenue decline, the company has increased its R&D investment by 11.20% to 2.690 billion yuan, which now accounts for 19.97% of revenue [3]. - Sales expenses also rose by 11.81% to 4.439 billion yuan, with the number of sales personnel increasing by nearly 60% from 3,155 to 4,995 [3]. - However, the number of R&D personnel decreased by 4.89%, from 1,329 to 1,264 [3]. Product Development - The company has several key products in development, including a new pediatric cough syrup and treatments for gout and other conditions, with some products expected to be approved this year [4][5]. - Notably, the company decided to terminate a U.S. application for a long-acting growth hormone, resulting in a 133 million yuan impairment charge that affected 2024 profits [6].

Core Viewpoint - Changchun High-tech reported strong financial performance for 2024, with significant revenue and profit growth, alongside a robust commitment to R&D and shareholder returns [1][5] Financial Performance - The company achieved operating revenue of 13.466 billion yuan and a net profit of 2.583 billion yuan for the reporting period [1] - Basic earnings per share were reported at 6.42 yuan, with a cash dividend of 26 yuan per 10 shares (tax included) [1] - For Q1 2025, the company reported operating revenue of 2.997 billion yuan and a net profit of 473 million yuan, with basic earnings per share of 1.17 yuan [5] R&D Investment - R&D investment reached 2.690 billion yuan, an increase of 11.20% year-on-year, accounting for 19.97% of operating revenue [1] - R&D expenses were 2.167 billion yuan, up 25.75% from the previous year, driven by accelerated new product development and talent acquisition [1][2] Product Development and Market Expansion - The company has 24 key products in clinical stages, with several new products receiving registration certificates and market approvals [2] - In 2024, Changchun High-tech accelerated international sales of growth hormone products, achieving sales revenue of 99 million yuan in foreign markets, a 454% increase year-on-year [2] Strategic Focus - The company aims to enhance new drug development capabilities, focusing on high-growth and high-value areas, while ensuring project management and market-driven innovation [3] - Plans include advancing vaccine development for infectious disease prevention and control, with a focus on high-demand human vaccines [3] AI Integration - Changchun High-tech is integrating AI technology into its R&D and management processes, enhancing efficiency across drug discovery, design, and production [4] - The company has made breakthroughs in antibody design using AI models, leading to cost reductions and improved production efficiency [4] Shareholder Returns - The company has established a three-year shareholder return plan, distributing a cash dividend of 4.5 billion yuan for 2023, totaling 1.847 billion yuan in cash dividends since its listing [5] - Cumulative cash dividends and share buybacks amount to 4.967 billion yuan, exceeding the total cash raised from various fundraising activities [5]

长春高新技术产业（集团）股份有限公司 控股股东及其他关联方资金占用情况的 专项说明 大华核字[2025]0011003381 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 长春高新技术产业（集团）股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项 说明 1-2 二、 长春高新技术产业（集团）股份有限公司 2024 年度非经营性资金占用及其他关联资金往来 情况汇总表 1 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 大华核字[2025] 0011003381 号 长春高新技术产业（集团）股份有 ...

（截止 2024 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 长春高新技术产业（集团）股份有限公司 内部控制审计报告 大华内字[2025]0011000094 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 长春高新技术产业（集团）股份有限公司 内部控制审计报告 1-2 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 内 部 控 制 审 计 报 告 大华内字[2025] 0011000094 号 长春高新技术产业（集团）股份有限公司全体股东： 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于 ...

长春高新技术产业（集团）股份有限公司 审计报告 大华审字[2025] 0011000214 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 长春高新技术产业（集团）股份有限公司 审计报告及财务报表 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-6 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1- 92 | 大华会计师事务所（特殊普通合伙） 北京市 ...